{"product_id":"phosimer-80-osimertinib","title":"LUTRODX (Lusutrombopag)","description":"\u003ch2\u003eAbout  Lusutrombopag\u003c\/h2\u003e\u003cp\u003eLusutrombopag is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures.\u003c\/p\u003e\u003ch2\u003eThrombocytopenia\u003c\/h2\u003e\u003cp\u003eIndicated for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure\u003c\/p\u003e\u003cp\u003eBegin dosing 8-14 days prior to scheduled procedure\u003c\/p\u003e\u003cp\u003ePatients should undergo their procedure 2-8 days after the last dose\u003c\/p\u003e\u003cp\u003eRecommended dose: 3 mg PO qDay for 7 days\u003c\/p\u003e\u003cp\u003eAlso see Administration\u003c\/p\u003e\u003ch2\u003eDosage Modifications\u003c\/h2\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl 30-90 mL\/min): No clinically meaningful effects on the pharmacokinetics\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min) or hemodialysis: Limited data\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (Child-Pugh A or B): No clinically meaningful effects on the pharmacokinetics\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Mean observed peak plasma concentration and AUC decreased by 20-30% in patients (compared with patients with Child-Pugh A and B); however, ranges for peak plasma concentration and AUC overlapped among patients with Child-Pugh class A, B, and C liver disease\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eInvestigated only as a single 7–day, once-daily dosing regimen in clinical trials in patients with chronic liver disease\u003c\/p\u003e\u003cp\u003eNot to be administered to patients with chronic liver disease in an attempt to normalize platelet counts\u003c\/p\u003e\u003ch4\u003eMonitoring\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eObtain a platelet count prior to initiating and not more than 2 days before the procedure\u003c\/li\u003e\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797946167339,"sku":"RL241010","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-0829-jpg.webp?v=1787022069","url":"https:\/\/xomeds.com\/products\/phosimer-80-osimertinib","provider":"XOMEDS","version":"1.0","type":"link"}